Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 120

Sort by

Sort Order Select

Journal Articles

Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)

Thierry Lamy, Cedric Pastoret, Gandhi Damaj, Olivier Tournilhac, Emmanuel Bachy, Loic Ysebaert, Frederique Orsini Piocelle, Anne Banos, Marianne Schwarz, Estibaliz Lazaro, Pierre Feugier, Hugo Gonzalez, Alain Renault, Milena Kohn, Roch Houot, Mikael Roussel, Eric Bellissant

Blood (2024) 144 (Supplement 1): 979.

https://doi.org/10.1182/blood-2024-200266

Published: 2024

Journal Articles

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Blood (2024) 144 (Supplement 1): 1871.

https://doi.org/10.1182/blood-2024-203269

Published: 2024

Journal Articles

Early Metabolic Response and Tmtv Are Key Predictors of Control of Relapse/Refractory Follicular Lymphoma Treated with CAR-T Cells : Preliminary Results from the French Descar-T Registry

Yassine Al Tabaa, Xavier Pallard, Loic Ysebaert, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Guillaume Cartron, Catherine Thieblemont, Didier Blaise, Cedric Rossi, Francoise Kraeber-Bodere, Benoit Tessoulin, Fabien Le Bras, Olivier Hermine, Emelie Van Zele, Vivien Dupont, Romain Ricci

Blood (2024) 144 (Supplement 1): 7131.

https://doi.org/10.1182/blood-2024-200968

Published: 2024

Journal Articles

Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study

Blood (2024) 144 (Supplement 1): 1856.

https://doi.org/10.1182/blood-2024-198200

Published: 2024

Journal Articles

French Regional Experience of Pre-CAR-T Cells Lymphodepleting Chemotherapy Outcourced in the Patient's Referring Center

Blood (2024) 144 (Supplement 1): 7612.

https://doi.org/10.1182/blood-2024-201541

Published: 2024

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Blood (2024) 144 (Supplement 1): 584.

https://doi.org/10.1182/blood-2024-194593

Published: 2024

Journal Articles

Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

Marion Aymard, Morgane Cheminant, Roch Houot, Anne Cuozzo, Elodie Gat, Catherine Thieblemont, Laure Ricard, Louise Roulin, Krimo Bouabdallah, Violaine Safar, Stephanie Guidez, Amandine Fayard, Gabriel Brisou, Loic Ysebaert, Olivier Hermine, Benoit Tessoulin, Charles Herbaux, Steven Le Gouill, Clementine Sarkozy

Blood (2024) 144 (Supplement 1): 239.

https://doi.org/10.1182/blood-2024-198920

Published: 2024

Journal Articles

Initiating First-Line (1L) Fixed-Duration (FD) Ibrutinib and Venetoclax (Ibr+Ven) in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched General European Population

Paolo Ghia, Loic Ysebaert, Ann Janssens, Mohamed Fouad, Claudio Schioppa, Jose-Angel Hernandez Rivas, Alessandra Tedeschi

Blood (2024) 144 (Supplement 1): 3254.

https://doi.org/10.1182/blood-2024-203883

Published: 2024

Journal Articles

Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy

Peter A. Riedell, Krish Patel, Vanessa Dunleavy, Yasmin H. Karimi, Nirav N. Shah, Vincent Ribrag, Loic Ysebaert, Robin Noel, Gabriel Brisou, Justin Kline, Chet Bohac, Carlos Naranjo, Jitendra Kanodia, Jacky Woo, Nancy Chen, Jean-Marie Michot, Benoîtt Tessoulin, Sairah Ahmed

Blood (2024) 144 (Supplement 1): 4497.

https://doi.org/10.1182/blood-2024-203668

Published: 2024

Journal Articles

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Blood (2023) 142 (Supplement 1): 297.

https://doi.org/10.1182/blood-2023-185057

Published: 2023

Journal Articles

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Blood (2023) 142 (Supplement 1): 634.

https://doi.org/10.1182/blood-2023-177713

Published: 2023

Journal Articles

Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study

Blood (2023) 142 (Supplement 1): 893.

https://doi.org/10.1182/blood-2023-177703

Published: 2023

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Blood (2023) 142 (Supplement 1): 3268.

https://doi.org/10.1182/blood-2023-173341

Published: 2023

Journal Articles

Autoimmune Cytopenia Associated with Indolent B-Cell Clones: A Large Multicentric Cohort Study

Blood (2023) 142 (Supplement 1): 800.

https://doi.org/10.1182/blood-2023-178535

Published: 2023

Journal Articles

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Sarka Pavlova, Jitka Malcikova, Lenka Radova, Silvia Bonfiglio, Jack B. Cowland, Christian Brieghel, Mette Klarskov Andersen, Maria Karypidou, Bella V Biderman, Michael Doubek, Gregory Lazarian, Inmaculada Rapado, Matthijs Vynck, Naomi Porret, Martin Andres, Dina Rosenberg, Dvora Sahar, Carolina Martinez-Laperche, Ismael Buño Borde, Andrew Hindley, Julio Bravo Sánchez, José García-Marco, Alicia Serrano, Blanca Ferrer Lores, Concepción Fernández-Rodriguez, Beatriz Bellosillo, Stephan Stilgenbauer, Eugen Tausch, Hero Nikdin, Fiona Quinn, Emer Atkinson, Lisette Van De Corput, Cafer Yildiz, Cristina Bilbao, Yanira Florido, Christian Thiede, Caroline Schuster, Anastazja Stoj, Sylwia Czekalska, Anastasia Chatzidimitriou, Stamatia Laidou, Audrey Bidet, Charles Dussiau, Friedel Nollet, Giovanna Piras, Tereza Borosova, Terezia Kurucova, Maria Monne, Svetlana Smirnova, Evgeny Nikitin, Ivan Sloma, Marie-Helene Delfau, Laetitia Largeaud, Loic Ysebaert, Peter J. M. Valk, Amy Christian, Renata Walewska, Marta Sebastião, Maria Gomes da Silva, Piero Galieni, Mario Angelini, Davide Rossi, Valeria Spina, Sónia Matos, Vânia Martins, David Donaldson, Tomasz Stoklosa, Monika Pepek, Panagiotis Baliakas, Rafa Andreu, Irene Luna, Tiina Kahre, Ülle Murumets, Sophie Laird, Daniel Ward, Miguel Alcoceba, Ana Balanzategui, Lydia Scarfo, Francesca Gandini, Ettore Zapparoli, Adoracion Blanco, Pau Abrisqueta Costa, Ana E. Rodriguez, Maria Rocio Benito Sanchez, Frédéric Davi, Clothilde Bravetti, Paula Gameiro, Joaquin Martinez-Lopez, Barbara Tazon, Fanny Baran-Marszak, Zadie Davies, Mark Caterwood, Andrey B Sudarikov, Richard Rosenquist, Carsten Utoft Niemann, Kostas Stamatopoulos, Paolo Ghia, Sarka Pospisilova

Blood (2023) 142 (Supplement 1): 200.

https://doi.org/10.1182/blood-2023-173235

Published: 2023

Journal Articles

Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa

Loic Ysebaert, Roch Houot, Olivier Casasnovas, Choquet Sylvain, Fabrice Jardin, Michael Loschi, Gabriel Brisou, Catherine Thieblemont, Jacques-Olivier Bay, Cristina Castilla-Llorente, Tom Fradon, Steven Le Gouill, Franck Morschhauser, Guillaume Cartron, Emmanuel Bachy

Blood (2023) 142 (Supplement 1): 296.

https://doi.org/10.1182/blood-2023-184653

Published: 2023

Journal Articles

Outcomes of CLL Patients Exposed to Venetoclax+/-R after Ibrutinib in France: The Resist Retrospective Study from the Filo-CLL Group

Loic Ysebaert, Emmanuelle Ferrant, Marie Sarah Dilhuydy, Anne-Sophie Michallet, Luca Inchiappa, Romain Guieze, Emmanuelle Tchernonog, Ana Cavillon, Marie Christine Bene, Luc-Matthieu Fornecker

Blood (2023) 142 (Supplement 1): 3273.

https://doi.org/10.1182/blood-2023-180696

Published: 2023

Journal Articles

Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study

Clementine Sarkozy, Thierry Jo Molina, Roch Houot, Sydney Dubois, Gian Matteo Pica, Philippe Ruminy, Charles Herbaux, Thomas Gastinne, Corinne Haioun, Stephanie Guidez, Christophe Bonnet, Marc Andre, Liana Vereseza, Choquet Sylvain, Loic Ysebaert, Emmanuel Bachy, Fabrice Jardin, Franck Morschhauser, Vincent Ribrag

Blood (2023) 142 (Supplement 1): 853.

https://doi.org/10.1182/blood-2023-174607

Published: 2023

Journal Articles

Post-Transplant Lymphoproliferative Disorders (PTLD) in Real Life: Data from the French K-Virogref Registry on 525 Adult Patients

Blood (2023) 142 (Supplement 1): 443.

https://doi.org/10.1182/blood-2023-189133

Published: 2023

Journal Articles

Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL

Blood (2023) 141 (26): 3166–3183.

https://doi.org/10.1182/blood.2022017839

Published: 2023

Includes: Supplemental data

NARROW

Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Early Metabolic Response and Tmtv Are Key Predictors of Control of Relapse/Refractory Follicular Lymphoma Treated with CAR-T Cells : Preliminary Results from the French Descar-T Registry

Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study

French Regional Experience of Pre-CAR-T Cells Lymphodepleting Chemotherapy Outcourced in the Patient's Referring Center

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

Initiating First-Line (1L) Fixed-Duration (FD) Ibrutinib and Venetoclax (Ibr+Ven) in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched General European Population

Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Autoimmune Cytopenia Associated with Indolent B-Cell Clones: A Large Multicentric Cohort Study

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa

Outcomes of CLL Patients Exposed to Venetoclax+/-R after Ibrutinib in France: The Resist Retrospective Study from the Filo-CLL Group

Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study

Post-Transplant Lymphoproliferative Disorders (PTLD) in Real Life: Data from the French K-Virogref Registry on 525 Adult Patients

Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only